ABCB10 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the ABCB10 gene in the human 143B osteosarcoma cell line. The polyclonal format provides a heterogeneous loss-of-function model without single-cell cloning, ideal for functional genomics and drug discovery studies that benefit from population-level analysis.
The host 143B cell line is a widely used human osteosarcoma model with epithelial morphology and mutant p53. Derived from a primary bone tumor, these cells are central to bone cancer research, including investigations of metastasis, therapeutic resistance, and metabolic reprogramming, making them a relevant background for mitochondrial gene knockout studies.
ABCB10 encodes a mitochondrial inner membrane transporter essential for heme biosynthesis. It stabilizes mitoferrin-1 (SLC25A37), facilitating mitochondrial iron import, and is transcriptionally controlled by GATA1, GATA2, and NFE2L2 (NRF2). ABCB10 interacts with ferrochelatase (FECH) and SUCLG1, and its downstream targets include ALAS2 and HMOX1. Loss of ABCB10 disrupts heme production and exacerbates oxidative stress, linking its function to disorders such as erythropoietic protoporphyria and microcytic anemia.
In 143B cells, ABCB10 knockout enables dissection of mitochondrial iron transport in osteosarcoma metabolism. The p53-mutant background, coupled with disrupted heme synthesis, may unmask vulnerabilities to oxidative damage and ferroptosis. This model supports analysis of how mitochondrial transporter defects influence cell proliferation, survival, and drug sensitivity in bone cancer, and can be used to explore redox signaling pathways intersecting with oncogenesis.
Recommended applications include erythropoiesis and heme metabolism assays, mitochondrial function studies, and oxidative stress profiling. Compatible techniques include western blotting, heme measurement, ROS detection, qPCR for erythroid markers, hemoglobin staining, flow cytometry, Seahorse analysis, and iron-55 uptake assays. The knockout population is also suitable for drug screening targeting porphyria or anemia. For further technical details or ordering information, please contact Ascent Research.
